Clinical Trial Update: Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease [Phase 4]

View source ↗

Summary

Phase 4 trial update investigating marinobufagenin as a target for DIGIBIND (digoxin immune Fab) in hypertensive patients with end-stage renal disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Hypertension

Drugs mentioned

• DIGIBIND (digoxin immune Fab)
• Marinobufagenin (marinobufagenin)

Snippet

Sponsor: National Institute on Aging (NIA) | Conditions: Hypertension, Hemodialysis | Phase 4 | Status: UNKNOWN